Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Xueyan ChenE Estey

Abstract

Both presence of minimal residual disease (MRD) and achievement of complete remission (CR) with incomplete platelet recovery (CRp) rather than CR after induction therapy predict relapse in acute myeloid leukemia (AML). These results suggest a correlation between response (peripheral count recovery) and MRD at the time of morphologic remission. Here we examine this hypothesis and whether MRD and response provide independent prognostic information after accounting for other relevant covariates. We retrospectively analyzed data from 245 adults with AML who achieved CR, CRp, or CR with incomplete blood count recovery (CRi) after induction therapy. Bone marrow samples were collected on or closest to the first date of blood count recovery, and MRD was determined by 10-color multiparameter flow cytometry. The 71.0% of patients who achieved CR had MRD less frequently and had lower levels of MRD than the 19.6% of patients achieving CRp and 9.4% achieving CRi. Although pretreatment covariates such as cytogenetics, monosomal karyotype, relapsed or refractory rather than newly diagnosed AML, and FLT3 internal tandem duplication were associated with relapse, their prognostic effect was much lower once MRD and response were taken into accoun...Continue Reading

References

Dec 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards
Mar 11, 2004·Blood Reviews·Krzysztof MrózekClara D Bloomfield
Aug 13, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dimitri A BreemsBob Löwenberg
Jun 10, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David GrimwadeAlan K Burnett
Feb 2, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roland B WalterJohn M Pagel
May 11, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jan KrönkeKonstanze Döhner
Feb 13, 2013·Lancet·Felicetto Ferrara, Charles A Schiffer
Sep 26, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Monique TerwijnGerrit J Schuurhuis
Sep 26, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sylvie D FreemanAlan K Burnett

❮ Previous
Next ❯

Citations

Dec 15, 2015·Blood·Hervé Dombret, Claude Gardin
Nov 23, 2015·Best Practice & Research. Clinical Haematology·Elisabeth Paietta
Nov 23, 2015·Best Practice & Research. Clinical Haematology·Frederick R Appelbaum
May 24, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Roland B Walter
Jun 27, 2015·Seminars in Hematology·Elihu Estey
Apr 12, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Moreno FestucciaBart L Scott
Jul 2, 2016·Blood Cancer Journal·I De Kouchkovsky, M Abdul-Hay
Jul 16, 2016·American Journal of Hematology·Elihu Estey
Aug 16, 2016·Clinical Lymphoma, Myeloma & Leukemia·Nicholas J Short, Farhad Ravandi
Aug 11, 2016·The New England Journal of Medicine·Robert K HillsUNKNOWN UK National Cancer Research Institute (NCRI) AML Working Group
Oct 25, 2016·Future Oncology·Maliha KhanTapan M Kadia
Dec 17, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Renato Bassan
Aug 19, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Xueyan ChenElihu H Estey
Aug 19, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Donna PrzepiorkaAnn T Farrell
Apr 8, 2017·Leukemia·C S HouriganR B Walter
Dec 9, 2016·Current Opinion in Hematology·Francesco Buccisano, Roland B Walter
Jan 30, 2018·Nature Reviews. Cancer·Marlise R LuskinDavid M Weinstock
Dec 16, 2017·The Annals of Pharmacotherapy·Nathan D SeligsonSalil Goorha
Mar 31, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sylvie D FreemanNigel H Russell
Jan 4, 2018·International Journal of Cancer. Journal International Du Cancer·Sameer SalunkheShilpee Dutt
Dec 9, 2017·Hematological Oncology·Francis LacombeUNKNOWN Groupe d'Etude Immunologique des Leucémies (GEIL)
Oct 25, 2017·Current Hematologic Malignancy Reports·Rahul S Vedula, R Coleman Lindsley
Oct 14, 2017·Current Hematologic Malignancy Reports·Francesco BuccisanoRoland B Walter
Nov 4, 2017·Current Hematologic Malignancy Reports·Yi Zhou, Brent L Wood
Sep 21, 2018·Leukemia & Lymphoma·Christine M McMahon, Alexander E Perl
Oct 27, 2017·Pediatrics International : Official Journal of the Japan Pediatric Society·Hidemasa MatsuoKeizo Horibe
Mar 29, 2019·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Mats Ehinger, Louise Pettersson
Jun 14, 2018·Blood Advances·Farhad RavandiSylvie D Freeman
Jan 3, 2020·Current Opinion in Hematology·Giovangiacinto PaternoAdriano Venditti

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.